Cargando…
Benefits of Early Systemic Corticosteroid in Clinical Deterioration of Post–COVID-19 Interstitial Lung Disease
Autores principales: | An, Tai Joon, Lee, Ye Jin, Park, Ji Eun, Lee, Eung Gu, Kim, Youlim, Kang, Sung-Yoon, Joo, Hyonsoo, Choi, Joon Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537655/ https://www.ncbi.nlm.nih.gov/pubmed/35950320 http://dx.doi.org/10.4046/trd.2022.0072 |
Ejemplares similares
-
Predicting unexpected deterioration of high-risk hospitalized patients during the COVID-19 pandemic: A multicenter cohort study
por: Kim, Sang Hyuk, et al.
Publicado: (2021) -
Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023) -
Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department
por: Jang, Hye Jin, et al.
Publicado: (2021) -
A Sudden Deterioration in Cognitive Functions as the Result of a Central Nervous System Lymphoma
por: Lee, Yongkyung, et al.
Publicado: (2018) -
Successful Treatment of Glycine-Receptor-Antibody-Mediated Progressive Encephalomyelitis with Rigidity and Myoclonus by Combining Steroids and Azathioprine
por: Lee, Eung-Joon, et al.
Publicado: (2019)